Ibogaine is a Schedule 1 controlled substance in Ireland, making its possession, supply, and production illegal under the Misuse of Drugs Act 1977 and its subsequent amendments. Last verified: April 22, 2026.

Current Legal Status

In Ireland, ibogaine is controlled under the Misuse of Drugs Act 1977 (as amended by the Misuse of Drugs Act 1984 and subsequent regulations). The substance is listed in Schedule 1 of the Misuse of Drugs Regulations 2017 (S.I. No. 173 of 2017), the most restrictive category, which covers substances deemed to have no accepted medical use and a high potential for abuse.

Under Schedule 1 classification in Ireland:

  • Possession is a criminal offence, with penalties including fines and imprisonment.
  • Supply, production, and importation carry more severe penalties — up to life imprisonment for large-scale supply offences under the Criminal Justice Act 1999.
  • Simple possession for personal use can result in a fine of up to €1,270 and/or up to 12 months' imprisonment on summary conviction for a first offence; repeat offences carry higher penalties.
  • There are no approved medical or therapeutic uses of ibogaine recognised by the Health Products Regulatory Authority (HPRA) in Ireland.

Religious or ceremonial exemptions: Unlike in some jurisdictions, Ireland does not recognise any religious carve-outs or exemptions for ibogaine use. There are no provisions under Irish law that permit its use for spiritual or ceremonial purposes, such as those that exist in countries with protections for indigenous plant-medicine traditions.

Research exemptions: A licence may theoretically be granted by the Minister for Health under Section 14 of the Misuse of Drugs Act 1977 for scientific research involving Schedule 1 substances, but no known active research licences for ibogaine have been publicly announced in Ireland.

Treatment Centers

There are no licensed ibogaine treatment clinics operating legally within Ireland. Because ibogaine is a Schedule 1 substance with no approved therapeutic status, any clinic administering ibogaine on Irish soil would be operating unlawfully under the Misuse of Drugs Act.

Irish nationals and residents seeking ibogaine-assisted therapy most commonly travel abroad to jurisdictions where treatment is legal or tolerated — most notably Portugal, Mexico, the Netherlands, South Africa, and Gabon. For a full international directory of operating clinics, see our ibogaine clinic directory.

Important: No facility in Ireland can legally administer ibogaine to patients. Be cautious of any operator within Ireland claiming to offer ibogaine therapy — such activity would be unlicensed and illegal.

How People Access Ibogaine in Ireland

This section describes how access occurs in practice, based on publicly available information. It does not constitute a recommendation or endorsement of any activity that may be unlawful.

  • Medical tourism: The most common route for Irish residents is travelling to a licensed or legally operating clinic abroad. Portugal's model of decriminalisation and the legal status of ibogaine in Mexico make both popular destinations. Some Irish individuals also travel to clinics in the Netherlands, South Africa, or Gabon.
  • Underground and informal settings: Anecdotal reports indicate that some people access ibogaine through informal networks within Ireland. This carries significant legal risk (criminal prosecution) and serious safety risks, as there is no medical oversight, screening, or emergency support.
  • Online procurement: Some individuals attempt to obtain ibogaine or iboga-containing products (such as total alkaloid extracts or root bark) through online vendors. Importation of a Schedule 1 substance into Ireland is a serious criminal offence and may attract attention from An Garda Síochána and Revenue's Customs Service.
Safety note: Ibogaine carries significant cardiac risks, including QT-interval prolongation and potentially fatal arrhythmias. Administration without proper medical screening, an ECG, and emergency protocols in place is extremely dangerous regardless of legal context.

Recent Legal Developments

Ireland has not amended the scheduling or legal status of ibogaine in recent years. However, the broader landscape of drug policy reform in Ireland has been evolving:

  • Citizens' Assembly on Drug Use (2023): The Citizens' Assembly on Drug Use published its final report in 2023, recommending a significant shift in Ireland's approach to drug policy — including a move toward health-led responses and, in some cases, decriminalisation of personal possession. The Assembly did not specifically address ibogaine but its recommendations signal growing political appetite for reform.
  • Government Response: The Irish Government's ongoing National Drugs Strategy and subsequent policy reviews have focused primarily on harm reduction for substances like heroin, cocaine, and cannabis. Psychedelic substances, including ibogaine, have not been included in any decriminalisation or rescheduling proposals currently before the Oireachtas.
  • European context: The European Medicines Agency (EMA) has not approved ibogaine as a medicinal product, and no EU-wide rescheduling discussions are currently underway that would affect Irish law.
  • Psychedelic research interest: Academic interest in psychedelic therapies — particularly psilocybin and MDMA — has grown in Ireland, with Trinity College Dublin and University College Dublin researchers involved in related fields. This has not yet extended to ibogaine-specific clinical research programmes in Ireland.

Risks of Seeking Treatment in Ireland

Seeking or obtaining ibogaine within Ireland carries layered risks:

  • Legal risk: Possession of ibogaine is a criminal offence. Depending on quantities, intent, and circumstances, prosecution could result in a criminal record, fines, or imprisonment. Supply or facilitation of supply carries significantly higher penalties.
  • No regulatory oversight: Because no legal framework exists for ibogaine therapy in Ireland, there are no standards, training requirements, or safeguards for informal providers. Patients have no recourse through the Medical Council, CORU, or HPRA if something goes wrong.
  • Medical safety: Ibogaine can cause serious cardiac events. In the absence of a clinical setting with pre-treatment cardiac screening (ECG, electrolyte panel) and emergency medical support, the risk of fatal arrhythmia is substantially elevated. Several deaths have been documented globally in unmonitored settings.
  • Substance purity: Products obtained through informal or online channels may be mislabelled, adulterated, or incorrectly dosed, compounding medical risks.
  • Psychological risks: Ibogaine produces intense, prolonged psychedelic experiences. Without proper psychological preparation, integration support, and a safe setting, the risk of acute psychological distress, trauma re-emergence, or lasting psychological harm is real.

Frequently Asked Questions

No. Ibogaine is a Schedule 1 controlled substance under the Misuse of Drugs Act 1977 and the Misuse of Drugs Regulations 2017 (S.I. No. 173 of 2017). Its possession, supply, production, and importation are all criminal offences in Ireland. There are no medical, religious, or ceremonial exemptions currently in place.
Travelling abroad to receive ibogaine treatment in a country where it is legal or tolerated is how many Irish residents access the therapy. Irish law does not have extraterritorial provisions criminalising ibogaine treatment received abroad. However, you must not bring ibogaine back into Ireland — importing a Schedule 1 controlled substance is a serious criminal offence under Irish and EU customs law. Always consult a legal professional and ensure you are receiving treatment at a reputable, medically supervised clinic. See our clinic directory for options.
Yes. The Misuse of Drugs Act 1977 and associated regulations control ibogaine as a chemical entity, and this extends to preparations, extracts, and plant material (such as Tabernanthe iboga root bark) that contain ibogaine or its alkaloids. Possessing or importing iboga root bark with ibogaine content is therefore also illegal in Ireland, not just the purified compound.
There are no current legislative proposals before the Oireachtas to reschedule or decriminalise ibogaine. The 2023 Citizens' Assembly on Drug Use recommended broader drug policy reform in Ireland, but its focus was primarily on common substances such as cannabis, heroin, and cocaine. Psychedelic therapy reform — where it is being discussed — tends to centre on psilocybin and MDMA. Any change to ibogaine's legal status in Ireland would require either a Ministerial Order under the Misuse of Drugs Act or primary legislation, neither of which appears imminent.
For simple possession of a Schedule 1 substance like ibogaine for personal use, penalties in Ireland can include a fine of up to €1,270 and/or up to 12 months' imprisonment on a first summary conviction. Repeat offences and offences heard on indictment carry heavier penalties. For possession with intent to supply, or for actual supply, manufacture, or importation, penalties are significantly more severe — up to life imprisonment is possible for large-scale trafficking under the Criminal Justice Act 1999 (which provides for mandatory minimum sentences where the street value of drugs involved exceeds €13,000).
Ireland's harm reduction infrastructure — including services operated by the HSE (Health Service Executive), the Ana Liffey Drug Project, and other organisations — is primarily focused on opioids, stimulants, and alcohol. There are no ibogaine-specific harm reduction services in Ireland. However, general harm reduction principles apply: if you are planning to use ibogaine in any context, cardiac screening (ECG) is critical, drug interactions (especially with opioids, SSRIs, and stimulants) must be checked, and a trusted person should be present. The HSE's drug and alcohol helpline (Freephone 1800 459 459) can provide general support and referrals.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.